We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-7.76%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.41B
AUM Growth
+$104M
Cap. Flow
+$94.2M
Cap. Flow %
6.7%
Top 10 Hldgs %
55.6%
Holding
106
New
20
Increased
33
Reduced
17
Closed
29

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$46.7M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$26.7M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$21M
5
ABMD
Abiomed Inc
ABMD
+$18.7M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$49M
2
HCA icon
HCA Healthcare
HCA
+$27.9M
3
MASI
Masimo
MASI
+$27.2M
4
ARKG icon
ARK Genomic Revolution ETF
ARKG
+$21.6M
5
RCM
R1 RCM Inc. Common Stock
RCM
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 70.04%
2 Miscellaneous 29.08%
3 Industrials 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$175M 12.47%
+465,000
New +$190M
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$92.2M 6.56%
632,794
-11,872
-2% -$1.52M
QQQ icon
3
PUT
Invesco QQQ Trust
QQQ
$489B
$75.7M 5.38%
270,000
+90,000
+50% +$27.9M
UTHR icon
4
United Therapeutics
UTHR
$22.1B
$73.2M 5.21%
310,834
+18,600
+6% +$3.78M
HZNP
5
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$71M 5.04%
889,583
+279,644
+46% +$26.5M
GSK icon
6
GSK
GSK
$102B
$69.9M 4.97%
1,275,297
+267,967
+27% +$14.8M
GSK icon
7
CALL
GSK
GSK
$102B
$67.6M 4.81%
1,242,960
– –
AZN icon
8
AstraZeneca
AZN
$252B
$67.4M 4.79%
510,165
+137,533
+37% +$18M
DHR icon
9
Danaher
DHR
$152B
$45.6M 3.24%
202,655
+22,437
+12% +$5.17M
SNY icon
10
Sanofi
SNY
$107B
$44M 3.13%
+879,460
New +$46.7M
AVTR icon
11
Avantor
AVTR
$9.86B
$34.8M 2.48%
1,120,175
+124,943
+13% +$3.9M
TEVA icon
12
Teva Pharmaceuticals
TEVA
$42.5B
$33.9M 2.41%
4,510,702
+367,100
+9% +$3.2M
CYH icon
13
Community Health Systems
CYH
$413M
$30.2M 2.15%
8,060,859
+934,148
+13% +$6.58M
XBI icon
14
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$26.4M 1.88%
+356,067
New +$26.7M
NVST icon
15
Envista
NVST
$4.36B
$25.4M 1.81%
659,094
+89,743
+16% +$3.77M
BIIB icon
16
Biogen
BIIB
$32.3B
$20.7M 1.47%
101,414
+23,411
+30% +$4.79M
ELV icon
17
Elevance Health
ELV
$85.5B
$20.6M 1.47%
42,785
+10,334
+32% +$5.11M
AZN icon
18
CALL
AstraZeneca
AZN
$252B
$19.8M 1.41%
150,150
-136,000
-48% -$17.8M
AMRN
19
Amarin Corp
AMRN
$295M
$19.8M 1.41%
664,245
+215,238
+48% +$9.29M
CNC icon
20
Centene
CNC
$32B
$19.8M 1.41%
233,647
+114,477
+96% +$9.51M
XBI icon
21
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$19.3M 1.37%
+259,800
New +$19.5M
SNDX icon
22
Syndax Pharmaceuticals
SNDX
$1.74B
$19.1M 1.36%
+994,362
New +$16.6M
ARGX icon
23
argenx
ARGX
$64B
$18.6M 1.32%
49,136
+25,994
+112% +$8.37M
FATE icon
24
Fate Therapeutics
FATE
$291M
$18M 1.28%
726,586
+270,527
+59% +$7.46M
AMRX icon
25
Amneal Pharmaceuticals
AMRX
$6.11B
$17.5M 1.24%
5,494,280
+2,783
+0.1% +$10.1K
1
2 3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Eversept Partners held 106 positions worth $1.41B, up 8% from $1.3B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Eversept Partners deployed $94.2M of net new capital in Q2 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Sanofi: 879,460 shares worth $44M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 79% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Masimo, an estimated $27.2M trimmed.

  • Eversept Partners's largest Q2 2022 buy was Sanofi: 879,460 shares worth $44M.
  • Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, an estimated $26.5M increase.
  • Eversept Partners's biggest Q2 2022 reduction was Masimo, cutting an estimated $27.2M.
  • Eversept Partners fully exited Ascendis Pharma A/S in Q2 2022, selling an estimated $49M.
  • Eversept Partners's ten largest holdings make up 56% of its $1.41B portfolio in Q2 2022.
  • Eversept Partners opened 20 new positions and closed 29 in Q2 2022.
  • Eversept Partners's portfolio value rose 8% quarter-over-quarter to $1.41B.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.